|
|
|
Volumn 52, Issue 8, 2011, Pages 618-626
|
|
[Novel monoclonal antibodies for the treatment of malignant lymphomas].
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
ANTIBODY CONJUGATE;
ANTINEOPLASTIC AGENT;
CAC10 VCMMAE;
CAC10-VCMMAE;
CANCER ANTIBODY;
CCR4 PROTEIN, HUMAN;
CD20 ANTIGEN;
CD22 ANTIGEN;
CD30 ANTIGEN;
CD52 ANTIGEN;
CHEMOKINE RECEPTOR CCR4;
GLYCOPROTEIN;
INOTUZUMAB OZOGAMICIN;
LEUKOCYTE ANTIGEN;
MOGAMULIZUMAB;
MONOCLONAL ANTIBODY;
OBINUTUZUMAB;
OFATUMUMAB;
TUMOR ANTIGEN;
ANIMAL;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL TRIAL (TOPIC);
DRUG ADMINISTRATION;
DRUG DESIGN;
FOLLICULAR LYMPHOMA;
HUMAN;
IMMUNOLOGY;
LARGE CELL LYMPHOMA;
MOLECULARLY TARGETED THERAPY;
MOUSE;
REVIEW;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTIBODIES, NEOPLASM;
ANTIGENS, CD;
ANTIGENS, CD20;
ANTIGENS, CD22;
ANTIGENS, CD30;
ANTIGENS, NEOPLASM;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG ADMINISTRATION SCHEDULE;
DRUG DESIGN;
GLYCOPROTEINS;
HUMANS;
IMMUNOCONJUGATES;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
LYMPHOMA, FOLLICULAR;
LYMPHOMA, LARGE B-CELL, DIFFUSE;
MICE;
MOLECULAR TARGETED THERAPY;
RECEPTORS, CCR4;
|
|
EID: 84855985827
PISSN: 04851439
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (1)
|
|
References (0)
|
